{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:41:27Z","timestamp":1790912487065,"version":"4.1.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Takeda Vaccines, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>An effective dengue vaccine should ideally induce broadly neutralizing antibody (nAb) responses against all 4 dengue virus (DENV) serotypes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We characterized the specificity and breadth of the nAb response to TAK-003, a live-attenuated tetravalent dengue vaccine, in serum samples from phase 2 and 3 clinical trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Microneutralization tests using postvaccination serum showed comparable neutralization against diverse DENV-1\u22124 genotypes. Reporter virus particle neutralization assays after depletion of anti-DENV-2 nAbs demonstrated that the nAb response to DENV-1, -3, and -4 comprises both type-specific (TS) and cross-reactive (CR) nAbs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Therefore, TAK-003 induces broad tetravalent TS and CR nAb responses.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiac272","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T16:20:28Z","timestamp":1656606028000},"page":"1959-1963","source":"Crossref","is-referenced-by-count":17,"title":["Specificity and Breadth of the Neutralizing Antibody Response to a Live-Attenuated Tetravalent Dengue Vaccine"],"prefix":"10.1093","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2147-557X","authenticated-orcid":false,"given":"Christina R","family":"DeMaso","sequence":"first","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Vaccines Business Unit , Cambridge, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lovkesh","family":"Karwal","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Vaccines Business Unit , Cambridge, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Zahralban-Steele","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Vaccines Business Unit , Cambridge, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dominguez","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Vaccines Business Unit , Cambridge, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang-Li","family":"Springer","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Vaccines Business Unit , Cambridge, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maima","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Vaccines Business Unit , Cambridge, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Palani","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Vaccines Business Unit , Cambridge, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Rindfleisch","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Vaccines Business Unit , Cambridge, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Bohning","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Vaccines Business Unit , Cambridge, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Hather","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Vaccines Business Unit , Cambridge, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subash","family":"Das","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Vaccines Business Unit , Cambridge, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuri","family":"Sharma","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Vaccines Business Unit , Cambridge, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansi J","family":"Dean","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Vaccines Business Unit , Cambridge, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,30]]},"reference":[{"key":"2022112908200731200_jiac272-B1","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(14)60572-9","article-title":"Dengue","volume":"385","author":"Guzman","year":"2015","journal-title":"Lancet"},{"key":"2022112908200731200_jiac272-B2","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/infdis\/jiu481","article-title":"Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort","volume":"211","author":"Corbett","year":"2015","journal-title":"J Infect Dis"},{"key":"2022112908200731200_jiac272-B3","doi-asserted-by":"crossref","first-page":"910","DOI":"10.4269\/ajtmh.2007.77.910","article-title":"Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences","volume":"77","author":"Gibbons","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"2022112908200731200_jiac272-B4","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/infdis\/jit273","article-title":"Reduced risk of disease during postsecondary dengue virus infections","volume":"208","author":"Olkowski","year":"2013","journal-title":"J Infect Dis"},{"key":"2022112908200731200_jiac272-B5","doi-asserted-by":"crossref","first-page":"e2357","DOI":"10.1371\/journal.pntd.0002357","article-title":"Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year","volume":"7","author":"Montoya","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"2022112908200731200_jiac272-B6","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg9478","article-title":"Dengue and Zika virus infections in children elicit cross-reactive protective and enhancing antibodies that persist long term","volume":"13","author":"Katzelnick","year":"2021","journal-title":"Sci Transl Med"},{"key":"2022112908200731200_jiac272-B7","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children and adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N Eng J Med"},{"key":"2022112908200731200_jiac272-B8","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.vaccine.2019.11.061","article-title":"Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: a phase 2, double-blind, randomised, controlled trial","volume":"38","author":"Tricou","year":"2020","journal-title":"Vaccine"},{"key":"2022112908200731200_jiac272-B9","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1473-3099(14)70811-4","article-title":"Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study","volume":"14","author":"Osorio","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2022112908200731200_jiac272-B10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009258","article-title":"Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003)","volume":"15","author":"White","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"2022112908200731200_jiac272-B11","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/infdis\/jiy063","article-title":"Analyzing the human serum antibody responses to a live attenuated tetravalent dengue vaccine candidate","volume":"217","author":"Swanstrom","year":"2018","journal-title":"J Infect Dis"},{"key":"2022112908200731200_jiac272-B12","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/infdis\/jiaa761","article-title":"Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents two years after vaccination","volume":"225","author":"L\u00f3pez-Medina","year":"2020","journal-title":"J Infect Dis"},{"key":"2022112908200731200_jiac272-B13","doi-asserted-by":"crossref","first-page":"e147066","DOI":"10.1172\/JCI147066","article-title":"Dengue vaccine breakthrough infections reveal properties of neutralizing antibodies linked to protection","volume":"131","author":"Henein","year":"2021","journal-title":"J Clin Invest"},{"key":"2022112908200731200_jiac272-B14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/infdis\/jiaa346","article-title":"Characterization of the type-specific and cross-reactive B cell responses elicited by a live-attenuated tetravalent dengue vaccine","volume":"223","author":"Michlmayr","year":"2020","journal-title":"J Infect Dis"},{"key":"2022112908200731200_jiac272-B15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.chom.2020.12.011","article-title":"Dengue vaccines: the promise and pitfalls of antibody-mediated protection","volume":"29","author":"Martinez","year":"2021","journal-title":"Cell Host Microbe"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiac272\/45212096\/jiac272.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/11\/1959\/47377002\/jiac272.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/11\/1959\/47377002\/jiac272.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T09:22:03Z","timestamp":1669713723000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/226\/11\/1959\/6623496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":15,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,6,30]]},"published-print":{"date-parts":[[2022,11,28]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiac272","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,6,30]]}}}